Evidence map›Paper›PMID 35001796›Full record

ArticlePharmaceutical biology2022

QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats.

Congyang Ding, Yajing Li, Xiao Li, Lu Meng, Ran Fu, Xiaonan Wang, Ying Li, Yinling Ma, Zhanjun Dong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Congyang DingNational Clinical Drug Monitoring Center, Hebei General Hospital, Shijiazhuang, China.
Yajing LiNational Clinical Drug Monitoring Center, Hebei General Hospital, Shijiazhuang, China.
Xiao LiNational Clinical Drug Monitoring Center, Hebei General Hospital, Shijiazhuang, China.
Lu MengDepartment of Pharmacy, The Second Hospital of Shijiazhuang, Shijiazhuang, China.
Ran FuGraduate School, Hebei Medical University, Shijiazhuang, China.
Xiaonan WangGraduate School, Hebei Medical University, Shijiazhuang, China.
Ying LiNational Clinical Drug Monitoring Center, Hebei General Hospital, Shijiazhuang, China.
Yinling MaNational Clinical Drug Monitoring Center, Hebei General Hospital, Shijiazhuang, China.
Zhanjun DongNational Clinical Drug Monitoring Center, Hebei General Hospital, Shijiazhuang, China.ORCID 0000-0001-5349-4970
Hebei General Hospital · CNHebei Medical University · CNFirst Hospital of Shijiazhuang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextAtorvastatin (ATV) and QiShenYiQi pills (QSYQ), a Chinese patent medicine, are often co-prescribed to Chinese cardiovascular patients. The effects of QSYQ on the pharmacokinetics of ATV have not been studied.

objectiveWe investigated the influence of QSYQ on the pharmacokinetics of ATV and its metabolites upon oral or intravenous administration of ATV to rats. MATERIALS AND

methodsSprague-Dawley rats (

resultsQSYQ resulted in an increase of AUC DISCUSSION AND

conclusionsQSYQ increased bioavailability of ATV administered orally through inhibiting the expression of Mrp2 in ileum. Clinicians should pay close attention to potential drug-drug interactions between ATV and QSYQ.

Indexed as

Herb-Drug InteractionsAnimalsArea Under CurveAtorvastatinATP-Binding Cassette TransportersBiological AvailabilityChromatography, High Pressure LiquidDrugs, Chinese HerbalHydroxymethylglutaryl-CoA Reductase InhibitorsIleumMaleRatsRats, Sprague-DawleyTandem Mass SpectrometryAbcc2 protein, ratAtorvastatinATP-Binding Cassette TransportersDrugs, Chinese HerbalHydroxymethylglutaryl-CoA Reductase Inhibitorsqishen yiqidrug-drug interactionMetabolic enzymestransporters

Identifiers

PMID35001796
PMCPMC8745373
OpenAlexW4206820232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.